Gilead’s Vemlidy expands label to treat paediatric chronic HBV
Pharmaceutical Technology
MARCH 29, 2024
Its label was expanded in 2022 for use in patients 12 years and older. Vemlidy was first approved to treat adults with HBV in 2016.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Pharmaceutical Technology
MARCH 29, 2024
Its label was expanded in 2022 for use in patients 12 years and older. Vemlidy was first approved to treat adults with HBV in 2016.
Fierce Pharma
DECEMBER 19, 2022
AbbVie's Vraylar, carrying $4B sales target, wins FDA label expansion in depression. Mon, 12/19/2022 - 11:13.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Healthcare
JANUARY 19, 2022
Bullish on growing use of telehealth, Wheel banks $150M to expand white-labeled virtual care services. Wed, 01/19/2022 - 16:26.
Fierce Pharma
NOVEMBER 14, 2022
AstraZeneca and Sanofi win big as Europe's human medicines committee endorses approvals, label expansions. Mon, 11/14/2022 - 08:59. fkansteiner.
The FDA Law Blog
DECEMBER 12, 2022
Shapiro — Last summer, FDA published a draft guidance, Laser-Assisted In Situ Keratomileusis (LASIK) Lasers – Patient Labeling Recommendations (July 29, 2022) setting forth a proposal for new recommended patient‑directed labeling. The approved devices already have patient‑directed labeling that FDA has approved.
Fierce Pharma
FEBRUARY 6, 2024
billion, a 16% increase from 2022. On a day when Vertex revealed trial data that indicate | On a day when Vertex revealed trial data that indicate its next-generation cystic fibrosis (CF) treatment will soon be ready to grab the baton, the Boston company also presented figures that show Trikafta remains formidable.
The Checkup by Singlecare
DECEMBER 8, 2022
Here’s a look at the 50 most-filled prescriptions of 2022. 50 most prescribed drugs of 2022. 1, 2022 through Oct. 31, 2022, excluding opioids and weight-loss drugs. Read on to learn more about the top 10 drugs of 2022. . It’s also frequently prescribed as an off-label treatment for fibromyalgia.” .
European Pharmaceutical Review
OCTOBER 24, 2023
Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 billion in 2022, the pharmaceutical packaging and labelling market in Europe is expected to expand at a compound annual growth rate (CAGR) of 4.78 percent in 2022. percent in 2022. billion in 2028, according to a report by Arizton.
The FDA Law Blog
SEPTEMBER 29, 2022
On September 14, 2022, the U.S. District Court for the Northern District of California ruled on a motion for summary judgement filed by the plaintiffs. Thus, the Court concluded that addition of the standalone text message disclosure options was inconsistent with the statute’s mandate.
OctariusRx
AUGUST 22, 2022
The 2022 version of the OctariusRx medication safety quiz is about to be released. The quiz focuses on some of the most commonly encountered situations, including allergies, labeling medications and controlled substances. The post Medication Safety Quiz 2022 appeared first on OctariusRX. How are you assessing your staff?
Digital Pharmacist
OCTOBER 24, 2022
Date of Approval: 9/30/2022. Date of Approval: 9/29/2022. Date of Approval: 9/22/2022. Date of Approval: 9/21/2022. Date of Approval: 9/14/2022. Date of Approval: 9/9/2022. Below we will be listing some of the new drug therapy advances and approvals that the FDA had in the month of September.
The FDA Law Blog
APRIL 21, 2024
But that’s the controversy here: Did FDA approve LYTGOBI NDA 214801 on September 30, 2022 when the Agency issued its initial approval letter , or on October 5, 2022 when FDA issued a corrected approval letter ? Rather, “permission for commercial marketing” was only effective upon FDA’s issuance of its corrected October 5, 2022 letter.
PharmaShots
FEBRUARY 1, 2023
Shots: The EC has approved a label expansion of Hemlibra (bispecific factor IXa- and factor X-directed Ab) in patients with a mod. 88.9%, respectively The decision was also based on real-world data while the label expansion will provide an effective & convenient prophylactic treatment option for patients with a mod. haemophilia A.
Drug Store News
JANUARY 4, 2023
H-E-B, Walmart, Kroger, Publix and ShopRite earned the top five spots in the most trusted private label products category.
The Checkup by Singlecare
DECEMBER 15, 2022
Comparitech , 2022). National Center for Education Statistics , 2022). Ditch the Label , 2017). Ditch the Label , 2017). Cyberbullying Research Center , 2022). Cyberbullying Research Center , 2022). Cyberbullying Research Center , 2022). The parents surveyed above said 19.2% Comparitech , 2018).
Drug Store News
FEBRUARY 17, 2023
In 2022, private label sales hit a new record, according to the Private Label Manufacturers Association.
The FDA Law Blog
APRIL 25, 2024
Promotional labeling is generally any labeling other than FDA-required labeling that is devised for the promotion of a product, as well as other functions, and can include printed, audio, or visual matter that describes the product. Comments to the revised draft guidance are due to the docket by June 25, 2024.
ISPE
MARCH 28, 2023
2022 ISPE China Pharmaceutical Supply Chain Summit Trudy Patterson Tue, 03/28/2023 - 09:24 iSpeak Blog iSpeak 2022 ISPE China Pharmaceutical Supply Chain Summit 28 March 2023 On 17 December 2022, more than 100 people from all over the world gathered online for the 2022 ISPE China Pharmaceutical Supply Chain Summit.
DiversifyRx
AUGUST 25, 2022
Colin Cross – White Labeling Supplements. There are many advantages to white-labeling your supplements, from increased loyalty to stable recurring revenue and even custom formulations. There are many advantages to white-labeling your supplements, from increased loyalty to stable recurring revenue and even custom formulations.
PharmaShots
APRIL 20, 2023
treatment interruption/discontinuation due to low lgG & lgM in (0.2% & 10.3%)/ (0.2% & 3.6%) patients Ref: Novartis | Image: Novartis Related News:- Novartis Presents Results of Kesimpta (ofatumumab) in P-III (ASCLEPIOS I/II) and (ALITHIOS) Open-Label Extension Trial for RMS at EAN 2022 vs switch group (-0.42%/yr.)
The FDA Law Blog
AUGUST 4, 2022
The American Conference Institute is hosting their 39th FDA Boot Camp from September 14-15, 2022. RECOGNIZE the pivotal role of labeling in the drugs and biologics approval process. The conference will be held virtually. GAIN a practical working knowledge of clinical trial process for pharmaceutical products.
ISPE
MARCH 28, 2023
Thanks to the clinical supply chain service companies' years of industry development and operation, there are new developments in global supply chain layout, ultra-low temperature storage and distribution management breakthroughs, and growing packaging and labeling capabilities. Special thanks to Ms. LTD Glace Life Technology (Shanghai) Co.,
pharmaphorum
JANUARY 12, 2021
Meanwhile, EMPEROR-Reduced also showed a slowdown in the rate of decline in kidney function among patients with HFrEF, an effect that Lilly and Boehringer are exploring in the CKD patient population in the EMPA-KIDNEY trial due to generate results in 2022.
pharmaphorum
JUNE 28, 2021
The duo are carrying out the EMPA-KIDNEY trial in CKD patients with and without diabetes, with results due in 2022, although it is possible that the study could be stopped early – like DAPA-CKD – if interim results are similarly strong. The post AZ closes in Forxiga kidney disease label in EU after nod from CHMP appeared first on.
Omnicell
FEBRUARY 17, 2023
A new era of IV robotics in the IVX Station , new technology introduced as part of Omnicell's Winter 2022 Release. It was also made with safety in mind, incorporating advanced vision systems, gravimetric verification, auto-labeling, and automatic application of tamper-evident caps for syringes.
STAT
JANUARY 8, 2024
The two men worked together from 2013 until 2022, when Jonas left to start a biotech incubator with funding from investment giant CBC Group. The VC firm has hired Jeff Jonas, Sage’s former chief executive, and Al Robichaud, Sage’s former chief scientific officer, as partners, the team told STAT exclusively.
STAT
JANUARY 9, 2023
Although artificial intelligence is entering health care with great promise, clinical AI tools are prone to bias and real-world underperformance from inception to deployment, including the stages of dataset acquisition, labeling or annotating, algorithm training, and validation.
pharmaphorum
APRIL 23, 2021
Calliditas Therapeutics is on course to launch its first product, Nefecon for rare disease primary IgA nephropathy (IgAN), in the first half of 2022 after getting the green light for an accelerated review by the EMA. . The post Calliditas eyes 2022 approval in EU for rare kidney disease drug Nefecon appeared first on.
Therapeutics Education Collaboration
SEPTEMBER 28, 2023
Show notes Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial Lancet 2022 Oct 22;400(10361):1417-1425 Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies (..)
The Checkup by Singlecare
DECEMBER 1, 2023
Department of Agriculture (USDA) requires it to be labeled “farmed” or” wild-caught.” Check the nutrition facts label to find the amount of vitamin D and other nutrients contained in individual products. The nutritional fact label will identify the recommended daily value of vitamin D suggested for the average adult.
The Checkup by Singlecare
APRIL 10, 2024
The Food and Drug Administration (FDA) first reported the shortage in December 2022, but availability issues have continued long after that. Though Mounjaro is not FDA approved for use as a weight loss drug, information about its weight loss effects has ramped up requests for off-label prescriptions of Mounjaro for weight loss.
STAT
JANUARY 10, 2024
Food and Drug Administration responded to decades of escalating concerns about Singulair, a widely prescribed drug for asthma and allergies, by adding a stark warning on the labeling that it could cause aggression, agitation and even suicidal thought. in 2022, The New York Times writes. The
The FDA Law Blog
DECEMBER 15, 2022
By Riëtte van Laack — On December 7, 2022, FDA announced the availability of the final guidance regarding the enforcement policy for homeopathic drug products. This concludes FDA’s reevaluation of the regulation of homeopathic drugs which it started in 2015.
BioPharm
NOVEMBER 20, 2022
This Application Note presents streamlined workflows for preparation of InstantPC and 2-AB labeled N-glycans coupled with analysis using Agilent LC/FLD/MS.
BioPharm
SEPTEMBER 28, 2022
This Application Note presents streamlined workflows for preparation of InstantPC and 2-AB labeled N-glycans coupled with analysis using Agilent LC/FLD/MS.
The Checkup by Singlecare
DECEMBER 21, 2023
Though metformin isn’t technically approved for use in treating anything other than diabetes, many healthcare providers prescribe it off-label because of the growing body of evidence supporting these added benefits. What is metformin approved to treat?
Therapeutics Education Collaboration
OCTOBER 4, 2022
2022 Apr 26;327(16):1610-1611. N Engl J Med 2022 Aug 18;387(7):599-610. N Engl J Med 2022; 387:790-798. N Engl J Med 2022; 387:790-798. 2022 Aug 5;8(8):e10104. 5) A systematic review of the stability of finished pharmaceutical products and drug substances beyond their labeled expiry dates. Show Notes.
The Checkup by Singlecare
NOVEMBER 9, 2023
The FDA approved tirzepatide under the brand name Mounjaro in May 2022 for Type 2 diabetes. Zepbound’s approval by the FDA may not necessarily mean more access to the medication, as many healthcare providers were already prescribing Mounjuro off-label (meaning for a use not approved by the FDA) for weight loss.
The Checkup by Singlecare
JANUARY 26, 2024
Healthcare professionals prescribe Ozempic off-label for weight management for patients with obesity. Approved by the Food and Drug Administration (FDA) in 2017 for blood sugar management, Ozempic has recently gained attention for its weight loss effects. It received FDA approval for weight management in June 2021.)
The FDA Law Blog
FEBRUARY 16, 2023
For the 12-month period ending September 2022, over 100,000 drug overdose deaths were reported. In August 2022, FDA announced the creation of the Overdose Prevention Framework with the vision to “undertake impactful, creative actions to prevent drug overdoses and reduce deaths.” What’s next?
Pharmaceutical Technology
NOVEMBER 25, 2022
In recent months, Wegovy (semaglutide), indicated for obesity, has been subjected to widespread supply shortages due to high demand, in addition to manufacturer production problems, with Novo Nordisk intending to relaunch Wegovy by the end of 2022.
pharmaphorum
OCTOBER 14, 2022
” The programme has been set up to develop four devices – an e-paper label, smart wearable sensor, smart pill box, and endo-cutter used in surgical procedures – with funding from the EU’s Horizon Europe programme and support from the Waste Electrical and Electronic Equipment (WEEE) Forum.
The Checkup by Singlecare
MARCH 25, 2024
In March 2022, the drug landed on the FDA’s list of drugs in short supply. Because those drugs are not FDA approved for weight loss, like Wegovy, healthcare providers may prescribe them off-label. When medications are prescribed off-label, there is a small chance that the patient’s insurance covers the medication.
Pharmaceutical Technology
DECEMBER 11, 2022
At the 2022 annual American Society of Hematology 2022 (ASH 2022) conference, being held between December 10-13, new data from the multi-arm , uncontrolled Phase I/II BRUIN study of pirtobrutinib were presented by Dr. These results pave the way for a new option for relapsed/refractory (R/R) RT patients.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content